NDA 020031 · Apotex
Paxil
Paroxetine Hydrochloride · Oral
NovelLast checked: Nov 19, 2026Latest source record: Sep 23, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1992
Dec 29, 1992
Approved uses
7
Original approval plus efficacy supplements
Registered trials
275
60 Phase 3, 11 recruiting
FAERS reports
54,135
33,774 serious, 3,560 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions ( 5.1 )] . PAXIL is not approved for use in pediatric patients [see Use in Specific Populations ( 8.4 )] . WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning . Increased risk of suicidal thoughts and behavior in pediatric and young adult patients taking antidepressants ( 5.1 ). Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors ( 5.1 ) PAXIL is not approved for use in pediatric patients ( 5.1 , 8.4 )
What it is approved for
From the label in effect Sep 29, 2026.
PAXIL is indicated in adults for the treatment of: Major depressive disorder (MDD) in adults Obsessive compulsive disorder (OCD) in adults Panic disorder (PD) in adults Social anxiety disorder (SAD) in adults Generalized anxiety disorder (GAD) in adults Posttraumatic stress disorder (PTSD) in adults PAXIL is a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of ( 1 ): Major depressive disorder (MDD) in adults Obsessive compulsive disorder (OCD) in adults Panic disorder (PD) in adults Social anxiety disorder (SAD) in adults Generalized anxiety disorder (GAD) in adults Posttraumatic stress disorder (PTSD) in adults
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 2, 2002 Supplement 35 · Efficacy Letter
- Dec 14, 2001 Supplement 29 · Efficacy LetterReviewLabel
- Apr 13, 2001 Supplement 26 · Efficacy LabelLetterReview
- May 11, 1999 Supplement 23 · Efficacy LetterLabel
- May 7, 1996 Supplement 9 · Efficacy
- May 7, 1996 Supplement 7 · Efficacy
- Dec 29, 1992 Original approval · Type 1 - New Molecular Entity Other Important Information from FDAPediatric Written RequestPediatric Amendment 1
5 products under this application
- PAXIL · PAROXETINE HYDROCHLORIDE EQ 50MG BASE · TABLET, ORAL · Discontinued
- PAXIL · PAROXETINE HYDROCHLORIDE EQ 20MG BASE · TABLET, ORAL · Prescription · TE AB
- PAXIL · PAROXETINE HYDROCHLORIDE EQ 40MG BASE · TABLET, ORAL · Prescription · TE AB
- PAXIL · PAROXETINE HYDROCHLORIDE EQ 30MG BASE · TABLET, ORAL · Prescription · TE AB
- PAXIL · PAROXETINE HYDROCHLORIDE EQ 10MG BASE · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Paroxetine" as an intervention, any sponsor and status, largest first.
- Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)Pivotal-lookingCompleted
National Institute of Mental Health (NIMH)NIH
NCT00012558 · 5,000 participants · Start Sep 1998
Drug: lithium; valproate and 6 more · For: Bipolar Disorder
Sites: Stanford, California; Denver, Colorado; Boston, Massachusetts · 11 sites in all
- Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)Pivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT01360866 · 2,944 participants · Start Oct 2011 · Primary completion Apr 18, 2017
Drug: OPC-34712; Escitalopram and 5 more · For: Depressive Disorder; Depression; Depressive Disorder, Major and 2 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 142 sites in all
Peking UniversityAcademic, hospital or other
NCT02023567 · 2,400 participants (planned) · Start Nov 2013 · Primary completion Dec 2016
Drug: SSRIs · For: Depressive Disorder, Major
Sites: Beijing, China; Shijiazhuang, China; Dalian, China · 9 sites in all
- Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant TreatmentPivotal-lookingCompleted
H. Lundbeck A/SIndustry
NCT01838681 · 1,986 participants · Start Jun 2013 · Primary completion Jun 2016
Drug: Placebo; Brexpiprazole and 1 more · For: Major Depressive Disorder
Sites: Little Rock, Arkansas; Cerritos, California; Temecula, California · 107 sites in all
BioNTech SEIndustry
NCT07070232 · 1,438 participants (planned) · Start Aug 12, 2025 · Primary completion Mar 2028
Drug: BNT326; Pumitamig and 2 more · For: Advanced Solid Tumor
Sites: Phoenix, Arizona; San Francisco, California; Hartford, Connecticut · 79 sites in all
- A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive DisorderPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT03538691 · 1,149 participants · Start Jul 13, 2018 · Primary completion Jul 8, 2022
Drug: Brexpiprazole; Antidepressant therapy · For: Major Depressive Disorder
Sites: Los Angeles, California
- Algorithm Guided Treatment Strategies for Major Depressive DisorderPivotal-lookingStatus unknown
Shanghai Mental Health CenterAcademic, hospital or other
NCT01764867 · 1,080 participants (planned) · Start Jun 2012 · Primary completion Oct 2014
Drug: Escitalopram; Mirtazapine and 11 more · For: Major Depressive Disorder
Sites: Shanghai, China
- Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)Pivotal-lookingCompleted
Forest LaboratoriesAbbVie (ABBV)
NCT01715805 · 1,022 participants · Start Nov 15, 2012 · Primary completion Jun 24, 2016
Drug: Cariprazine; Placebo and 1 more · For: Major Depressive Disorder
Sites: Tucson, Arizona; Little Rock, Arkansas; Cerritos, California · 85 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug withdrawal syndrome5,459
- nausea4,157
- drug ineffective3,844
- dizziness3,820
- anxiety3,794
- fatigue3,606
- headache3,242
- depression3,143
- drug exposure during pregnancy2,902
- insomnia2,645
- diarrhoea2,401
- weight increased2,350
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 5,814 |
| 2005 | 5,231 |
| 2006 | 4,161 |
| 2007 | 2,391 |
| 2008 | 2,508 |
| 2009 | 2,432 |
| 2010 | 2,821 |
| 2011 | 2,916 |
| 2012 | 2,742 |
| 2013 | 1,639 |
| 2014 | 1,702 |
| 2015 | 3,347 |
| 2016 | 3,009 |
| 2017 | 1,872 |
| 2018 | 1,636 |
| 2019 | 1,678 |
| 2020 | 1,452 |
| 2021 | 1,317 |
| 2022 | 1,262 |
| 2023 | 1,151 |
| 2024 | 1,179 |
| 2025 | 1,076 |
| 2026 | 793 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Paxil (Paroxetine HCl)
2024 spending
$1.7M
Beneficiaries
624
2,944 claims
Per beneficiary
$2,674
$9.40 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $3,869,382 |
| 2021 | $3,876,607 |
| 2022 | $2,752,938 |
| 2023 | $1,903,999 |
| 2024 | $1,668,362 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis.
Kishi T, Ikuta T, Sakuma K, et al. · Mol Psychiatry 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Cardiovascular effects of paroxetine.
Kuhs H, Rudolf GA · Psychopharmacology (Berl) 1990 · Clinical Trial, Comparative Study
- Cancer-related fatigue-pharmacological interventions: systematic review and network meta-analysis.
Chow R, Bruera E, Sanatani M, et al. · BMJ Support Palliat Care 2023 · Systematic Review, Network Meta-Analysis
- Pharmacological treatments for social anxiety disorder in adults: a systematic review and network meta-analysis.
Williams T, McCaul M, Schwarzer G, et al. · Acta Neuropsychiatr 2020 · Comparative Study, Network Meta-Analysis
- Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemotherapy.
Roscoe JA, Morrow GR, Hickok JT, et al. · Breast Cancer Res Treat 2005 · Clinical Trial, Comparative Study
- [Clinical effect and tolerance of paxil (paroxetine) in management of panic disorders].
Mosolov SN, Smulevich AB, Nuller IuL, et al. · Ter Arkh 2000 · Clinical Trial, English Abstract
Sponsor: Apotex
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.